Outlook Therapeutics (OTLK) director purchases 95,398 common shares
Rhea-AI Filing Summary
Outlook Therapeutics director Faisal Ghiath Sukhtian purchased 95,398 shares of common stock on July 29, 2026 at 1.0482 per share in an open-market or private transaction. After this buy, he directly owns 220,972 common shares. The transaction was not reported as made under a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 95,398 shares
Net Buy
1 txn
Insider
Sukhtian Faisal Ghiath
Role
Director
Bought
95,398 shs ($100K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 95,398 | $1.0482 | $100K |
Holdings After Transaction:
Common Stock — 220,972 shares (Direct)
Key Figures
Shares purchased: 95,398 shares
Purchase price: 1.0482 per share
Shares owned after transaction: 220,972 shares
+1 more
4 metrics
Shares purchased
95,398 shares
Common Stock acquired on 2026-07-29 in a non-derivative transaction
Purchase price
1.0482 per share
Per-share price for the 95,398 common shares bought
Shares owned after transaction
220,972 shares
Director’s direct common stock holdings following the reported purchase
Net shares bought
95,398 shares
Net common shares acquired across all transactions in this Form 4
Key Terms
Form 4, non-derivative, open market or private transaction
3 terms
Form 4 regulatory
"Insider transaction reported on SEC Form 4 for Outlook Therapeutics, Inc."
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
non-derivative financial
"The transaction_type is listed as "non-derivative" for the Common Stock purchase."
open market or private transaction financial
"The code description states "Purchase in open market or private transaction"."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Outlook Therapeutics (OTLK) disclose in this Form 4?
Outlook Therapeutics disclosed that director Faisal Ghiath Sukhtian bought 95,398 common shares. The purchase occurred on July 29, 2026 at a price of 1.0482 per share in an open-market or private transaction.
Was the Outlook Therapeutics (OTLK) insider trade under a Rule 10b5-1 plan?
The filing indicates the transaction was not made under a Rule 10b5-1 trading plan. The document-level 10b5-1 checkbox is marked false, so the July 29, 2026 purchase is not reported as pre-arranged under such a plan.
What type of security did the Outlook Therapeutics (OTLK) director purchase?
The director purchased Common Stock of Outlook Therapeutics in a non-derivative transaction. The Form 4 shows 95,398 common shares acquired directly, with total direct ownership rising to 220,972 common shares after the purchase.